Phase I dose-escalation and pharmacokinetic study of antrubicin in patients with recurrent advanced lung cancer.

被引：0
|
作者：
Okamoto, I
Hamada, A
Matsunaga, Y
Sasaki, JI
Fujii, S
Uramoto, H
Yamagata, H
Mori, I
Kishi, H
Semba, H
机构：
[1] Kinki Univ, Sch Med, Osaka 589, Japan
[2] Kumamoto Univ, Kumamoto, Japan
[3] Kumamoto Lung Canc Grp, Kumamoto, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：151S / 151S
页数：1
相关论文
共 50 条
  • [1] A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer.
    Leong, S.
    Camidge, R.
    Eckhardt, G.
    Basche, M.
    Musib, L.
    Darstein, C.
    Thornton, D.
    Britten, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 91S - 91S
  • [2] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [3] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Padda, Sukhmani K.
    Krupitskaya, Yelena
    Chhatwani, Laveena
    Fisher, George A.
    Colevas, Alexander D.
    Pedro-Salcedo, Melanie San
    Decker, Rodney
    Latz, Jane E.
    Wakelee, Heather A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 1013 - 1020
  • [4] A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
    Sukhmani K. Padda
    Yelena Krupitskaya
    Laveena Chhatwani
    George A. Fisher
    Alexander D. Colevas
    Melanie San Pedro-Salcedo
    Rodney Decker
    Jane E. Latz
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1013 - 1020
  • [5] Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer
    Juarez, Tiffany M.
    Piccioni, David
    Rose, Lara
    Nguyen, Angel
    Brown, Bradley
    Kesari, Santosh
    NEURO-ONCOLOGY ADVANCES, 2021, 3 (01)
  • [6] A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with docetaxel in patients with advanced solid tumors
    Robert, F.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    Vermeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Verkh, L.
    Traynor, A.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3514S - 3515S
  • [7] A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer
    Juarez, Tiffany M.
    Gill, Jaya M.
    Heng, Annie
    Carrillo, Jose A.
    Wagle, Naveed
    Nomura, Natsuko
    Nguyen, Minhdan
    Truong, Judy
    Dobrawa, Lucia
    Sivakumar, Walavan
    Barkhoudarian, Garni
    Kelly, Daniel F.
    Kesari, Santosh
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [8] A Phase I Dose-Escalation Study of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer
    Ullenhag, Gustav J.
    Rossmann, Eva
    Liljefors, Maria
    PLOS ONE, 2015, 10 (04):
  • [9] Phase I/II dose-escalation and expansion study of afuresertib plus carboplatin and paclitaxel in recurrent ovarian cancer.
    Blagden, Sarah Patricia
    Gabra, Hani
    Hamilton, Anne L.
    Wong, Shirley S.
    Michael, Agnieszka
    Mileshkin, Linda R.
    Hall, Marcia
    Goh, Jeffrey
    Lisyanskaya, Alla Sergeevua
    DeSilvio, Michelle
    Habr, Dany
    Gainer, Shelby
    Gopalakrishna, Prashanth
    Meniawy, Tarek
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] A phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer.
    Geenen, Jill J. J.
    Dackus, Gwen
    Schouten, Philip C.
    Pluim, Dick
    Marchetti, Serena
    Sonke, Gabe S.
    Huitema, Alwin
    Beijnen, Jos H.
    Schellens, Jan H. M.
    Linn, Sabine C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345